- Home
- SLNH vs SNY Comparison
SLNH vs SNY Comparison
Compare SLNH & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNH
- SNY
- Stock Information
- Founded
- SLNH 1961
- SNY 1994
- Country
- SLNH United States
- SNY France
- Employees
- SLNH N/A
- SNY N/A
- Industry
- SLNH EDP Services
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- SLNH Technology
- SNY Health Care
- Exchange
- SLNH Nasdaq
- SNY Nasdaq
- Market Cap
- SLNH 15.5M
- SNY 113.4B
- IPO Year
- SLNH N/A
- SNY N/A
- Fundamental
- Price
- SLNH $0.72
- SNY $47.03
- Analyst Decision
- SLNH Hold
- SNY Buy
- Analyst Count
- SLNH 1
- SNY 4
- Target Price
- SLNH N/A
- SNY $61.50
- AVG Volume (30 Days)
- SLNH 4.0M
- SNY 2.8M
- Earning Date
- SLNH 11-13-2025
- SNY 10-24-2025
- Dividend Yield
- SLNH N/A
- SNY 3.40%
- EPS Growth
- SLNH N/A
- SNY 118.56
- EPS
- SLNH N/A
- SNY 8.65
- Revenue
- SLNH $27,891,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- SLNH N/A
- SNY $2.01
- Revenue Next Year
- SLNH $32.19
- SNY $6.82
- P/E Ratio
- SLNH N/A
- SNY $10.74
- Revenue Growth
- SLNH N/A
- SNY 15.65
- 52 Week Low
- SLNH $0.36
- SNY $44.73
- 52 Week High
- SLNH $4.78
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- SLNH 69.16
- SNY 42.55
- Support Level
- SLNH $0.43
- SNY $46.79
- Resistance Level
- SLNH $0.79
- SNY $47.69
- Average True Range (ATR)
- SLNH 0.06
- SNY 0.71
- MACD
- SLNH 0.03
- SNY -0.27
- Stochastic Oscillator
- SLNH 79.64
- SNY 32.62
About SLNH Soluna Holdings Inc.
Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.